Journal of Clinical Virology
Volume 38, Issue 1 , Pages 32-38 , January 2007

Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy

  • Maribel Rodríguez-Torres

      Affiliations

    • Fundación de Investigación de Diego, San Juan, Puerto Rico
    • Ponce School of Medicine, Ponce, Puerto Rico
    • Corresponding Author InformationCorresponding author at: Fundación de Investigación de Diego, Ave. De Diego 359 Suite 302, Santurce 00909, Puerto Rico. Tel.: +787 722 1248; fax: +787 721 6098.
    • ,
  • José F. Rodríguez-Orengo

      Affiliations

    • Department of Biochemistry, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico
    • ,
  • Carlos F. Ríos-Bedoya

      Affiliations

    • Ponce School of Medicine, Ponce, Puerto Rico
    • ,
  • Alberto Fernández-Carbia

      Affiliations

    • University Pathologists, San Juan, Puerto Rico
    • ,
  • Elsa González-Lassalle

      Affiliations

    • Fundación de Investigación de Diego, San Juan, Puerto Rico
    • ,
  • Rosa Salgado-Mercado

      Affiliations

    • Fundación de Investigación de Diego, San Juan, Puerto Rico
    • ,
  • Acisclo M. Marxuach-Cuétara

      Affiliations

    • Fundación de Investigación de Diego, San Juan, Puerto Rico

Received 30 December 2005 ,Revised 20 June 2006 ,Accepted 19 September 2006.

References 

  1. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palù G, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol. 2005;42(5):615–624
  2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States 1988, through 1994. N Engl J Med. 1999;341(8):556–562
  3. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology. 1999;30:1054–1058
  4. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34:283–287
  5. Berg T, Van Wagner M, Hinrichsen H, Heintges T, Buggisch P, Goeser T, et al. Reduction of the relative relapse rate by prolongation of the duration of a therapy with peginterferon alfa-2a plus ribavirin in patients with genotype 1 infection up to 72 weeks. In: Proceedings of the 55th Annual meeting of the American Association for the Study of Liver Diseases. 2004;
  6. Bonacini M, Govindarajan S, Blatt JM, Schmid P, Conrad A, Lindsay KL. Patients coinfected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat. 1999;6:203–208
  7. Brau N, Bini EJ, Shahidi A, Aytaman A, Xiao P, Stancic S, et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol. 2002;97:2071–2078
  8. Center for Disease Control and Prevention (CDC). 2004. Website: http://www.cdc.gov/ncidod/diseases/hepatitis/C/fact.htm.
  9. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viremia and impaired antibody response in patients coinfected with HIV. AIDS. 1995;9:1131–1136
  10. Di Martino , Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34:1193–1199
  11. Di Martino V, Thevenot T, Boyer N, Cazals-Hatem D, Degott C, Valla D, et al. HIV co infection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C. AIDS. 2002;16:441–445
  12. Diago M, Romero-Gómez M, Crespo J, et al. Peg interferon alfa-2a (40kDa) (Pegasys) and ribavirin (Copegus) in patients infected with HCV genotype 1 and who failed to respond to interferon and ribavirin: final results of the Spanish high dose induction pilot trial. Hepatology. 2004;40(Suppl. 1):389A
  13. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis. 2004;189(6):964–970[Epub 2004 Feb 27]
  14. Enriquez J, Gallego A, Torras X, Perez-Olmeda T, Diago M, Soriano V, et al. Retreatment for 24 vs. 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepat. 2000;7(6):403–408
  15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med. 2002;347:975–982
  16. Gross , et al. Double dose Peg-interferon alfa-2a weight-based Ribavirin improves response for Interferon/Ribavirin non-responders with Hepatitis C: final results of RENEW study. San Francisco: AASLD; 2005;
  17. Hadziyannis SJ, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–355
  18. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;33:365–372
  19. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27–F36
  20. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. J Infect Dis. 1998;178:1189–1192
  21. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  22. Martínez-Sierra C, Arizcorreta A, Diaz F, Roldan R, Martin-Herrera L, Perez-Guzman E, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis. 2003;36:491–498
  23. Moskovitz DN, Manoharan P, Heathcote EJ. High dose consensus interferon in non-responders to interferon alpha-2b and ribavirin with chronic hepatitis C. Can J Gastroenterol. 2003;17:479–482
  24. Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS. 2004;18(1):75–79
  25. Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, et al. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previouslynon responsive to interferon: a randomized trial. J Viral Hepat. 2003;10:197–204
  26. Poynard T, Mathurin P, Cai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257–265
  27. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–1313
  28. Roche Laboratories. NV17318, randomized, multicenter, double-blind, phase IV pilot study evaluating the effect of Pegasys® doses of 180μg or 270μg in combination with Copegus® doses of 1200mg or 1600mg on viral kinetics, virological response, pharmacokinetics, and safety in interferon-naïve patients with chronic hepatitis C genotype 1 virus infection of high viral titer and body weight greater than 85kg, 2004.
  29. Rockstroh JK, Mudar M, Lichterfeld M, Nischalke HD, Klausen G, Golz J, et al. Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS. 2002;16:2082–2085
  30. Sanchez-Tapias J, Diago M, Escartin P, Enriquez J, Moreno R, Romero-Gomez M, et al. Longer treatment duration with peginterferon alfa-2a (40kDa) (Pegasys®) and ribavirin (Copegus®) in naïve patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter Teravic-4 study. In: Proceedings of the 55th Annual meeting of the American Association for the Study of Liver Diseases. 2004;
  31. Sherman KE, O’Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol. 1993;31:2679–2682
  32. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831–837
  33. Soriano V. Optiming response rates to Peg/RBV in coinfected patients: increased Ribavirin dosing; extending therapy duration. Highlights of the 2nd International Workshop on HIV and Hepatitis Coinfection, 2006.
  34. Soriano V, Perez-Olmeda M, Rios P, Nunez M, Garcia-Samaniego J, Gonzalez-Lahoz J. Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res Hum Retroviruses. 2004;20(4):351–353
  35. Teuber G, Pascu M, Berg T, Lafrenz M, Pausch J, Kullmann F, et al. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol. 2003;39(4):606–613
  36. Thuluvath PJ, Pande H, Maygers J. Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C non-responders to interferon and ribavirin. Dig Dis Sci. 2003;48:594–597
  37. Tien PC. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the veterans affairs hepatitis C resource center program and national hepatitis C program office. Am J Gastroenterol. 2005;100(10):2338–2354
  38. Torriani FJ, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438–450
  39. World Health Organization. Hepatitis: 170 million infected worldwide and still no vaccine. WHO Press Release. No. 36. May 1, 1998.
  40. Zein NN. The epidemiology and natural history of hepatitis C virus infection. Cleve Clin J Med. 2003;70(Suppl. 4):S2–S6

PII: S1386-6532(06)00345-3

doi: 10.1016/j.jcv.2006.09.009

Journal of Clinical Virology
Volume 38, Issue 1 , Pages 32-38 , January 2007

Article Tools

* Image Usage & Resolution